Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 7, 2026Cell Death and DiseaseOpen Access

Lactylation as a metabolic-epigenetic switch in cancer: dual roles in cell death resistance and therapeutic vulnerability

View Full Paper
Ask AI
Bookmark
Share

Authors

CYChengjiao YangRYRuici YangBZB Zheng

Discussion

Loading...

Member takes

Overview

This review highlights how lactylation influences cancer cell treatment resistance, suggesting new therapeutic targets.

Key Points

  • To explore the dual roles of lactylation in cancer resistance to therapy and its implications for treatment.
  • Reviewed recent advances in lactylation and its role in cancer.
  • Analyzed enzymatic and non-enzymatic lactylation mechanisms.
  • Discussed lactylation's interaction with other post-translational modifications (PTMs).
  • Examined therapeutic targeting of lactylation in preclinical and clinical studies.
  • Lactylation enhances both intrinsic and extrinsic resistance to therapies in cancer cells.
  • Targeting lactylation pathways showed synergistic effects with chemotherapy and immunotherapy.
  • Distinct lactylomic signatures can serve as predictive biomarkers for treatment outcomes.

Cite This Study

Yang et al. (2026) studied this question.

synapsesocial.com/papers/69abc1645af8044f7a4e9fc4https://doi.org/10.1038/s41419-026-08494-7
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance2024 · 549 citations
  2. 2Glycometabolic reprogramming-induced XRCC1 lactylation confers therapeutic resistance in ALDH1A3-overexpressing glioblastoma2024 · 223 citations
  3. 3Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti‐PD‐1 therapy in hepatocellular carcinoma2024 · 51 citations
  4. 4High-glucose-associated YTHDC1 lactylation reduces the sensitivity of bladder cancer to enfortumab vedotin therapy2025 · 30 citations
  5. 5Class I histone deacetylases (HDAC1–3) are histone lysine delactylases2022 · 626 citations